| Autor: |
Ivan Pourmir, Reza Elaidi, Zineb Maaradji, Hortense de Saint Basile, Monivann Ung, Benoit Gazeau, Laure Fournier, Bastien Rance, Laure Gibault, Mohammed Ismaili, Elizabeth Fabre |
| Rok vydání: |
2023 |
| DOI: |
10.1101/2023.03.09.23287023 |
| Popis: |
AimsAnti-PD-1/PD-L1 can face the issue of tumor resistance in advanced non-small cell lung cancer (aNSCLC), mostly as primary resistance to the treatment. Still, disease progression (PD) also occurs after prior durable clinical benefit (DCB). Comparison of both situations and tools to evaluate residual benefit of PD-1/PD-L1 blockade are needed to understand and manage resistance.MethodsWe reviewed aNSCLCs with anti-PD-1/PD-L1 monotherapy, and disease progression per RECIST 1.1 (PD) in our center. Primary objective was comparison of post-progression survival (PPS) in primary resistance versus PD after DCB. Secondary objectives were to characterize patterns of PD after DCB; assess the feasibility and relevance of Tumor Growth Rate (TGR) in PD after DCB.Results148 patients were included. Median PPS were 5.2months (95% CI: 2.6-6.5) and 21.3months (95% CI: 18.5-36.3) (pConclusionsPD after DCB was an independent factor of longer post-progression survival, with specific patterns of progression. TGR is a promising tool to assess residual benefit of immunotherapy.HighlightsAnti-PD-(L)1 immunotherapy still faces the problem of resistance in lung cancerResistance can be classified as primary or secondary (acquired)Outcomes and mechanisms of both situations need to be characterizedThis unique comparative study reveals diverging survival and progression patternsPrior durable clinical benefit associates with longer post-progression survivalThis data benefits our understanding and management of resistance to anti-PD-(L)1 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
